Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study

Findings on impact of mismatch repair deficiency (MMRd) on patient outcomes in endometrial cancer (EC) have been inconsistent to date. The objective of this study was to compare the oncologic outcomes and recurrence patterns between MMRd and MMR-intact (MMRi) endometrioid EC (EEC). Between 2015 and...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2021-04, Vol.161 (1), p.221-227
Main Authors: Kim, Soyoun Rachel, Tone, Alicia, Kim, Raymond H., Cesari, Matthew, Clarke, Blaise A., Eiriksson, Lua, Hart, Tae, Aronson, Melyssa, Holter, Spring, Lytwyn, Alice, Lajkosz, Katherine, Oldfield, Leslie, Gallinger, Steven, Bernardini, Marcus Q., Oza, Amit M., Djordjevic, Bojana, Lerner-Ellis, Jordan, Van de Laar, Emily, Vicus, Danielle, Pugh, Trevor, Pollett, Aaron, Ferguson, Sarah E.
Format: Article
Language:English
Subjects:
Endometrioid endometrial cancers
Mismatch repair deficiency
Prognostic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Findings on impact of mismatch repair deficiency (MMRd) on patient outcomes in endometrial cancer (EC) have been inconsistent to date. The objective of this study was to compare the oncologic outcomes and recurrence patterns between MMRd and MMR-intact (MMRi) endometrioid EC (EEC). Between 2015 and 2018, we prospectively recruited 492 EEC cases from three cancer centers in Ontario, Canada. Tumors were reflexively assessed for MMR protein expression by immunohistochemistry (IHC). Clinicopathological, survival and recurrence patterns were compared between MMRd and MMRi cases. Of 492 EEC, 348 were MMRi (71%) and 144 were MMRd (29%) with median follow-up of 16.8 months (0–69.6). MMRd tumors tended to be grade 2 or 3 (56% vs. 29%, p 
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2021.01.002